Printer Friendly

BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES RESULTS OF FIRST ANIMAL TESTS WITH ANTI-CANCER DRUG

 LYNBROOK, N.Y., Aug. 4 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today the preliminary results of the first animal test of its anti-cancer colchicine analogs. In this early test, the survival rates of the animals treated were better than some agents now widely used as cancer chemotherapeutics. In a test of survival of mice with leukemia, those treated with the test materials lived more than twice as long as control animals. These patented chemicals are derived from colchicine, a botanical used in medicine for many years, the structure of which has been modified by synthetic methods to improve the benefit-toxicity ratio. The company emphasized that these results were very early findings and much additional work must be done before the drugs reach human trials.
 Further research efforts, including toxicology, are now being expedited by the company.
 BioSpecifics, through its subsidiaries, produces and licenses pharmaceutical products for domestic and international sales. The company is also engaged in various stages of research, development, clinical testing and licensing of additional pharmaceutical products and therapeutically active molecules. The company's current principal product is its FDA-approved enzyme Collagenase ABC, used in topical applications for treatment of dermal ulcers and severely burned areas.
 -0- 8/4/93
 /CONTACT: Edwin H. Wegman, president of BioSpecifics Technologies Corp., 516-593-7000; or Sam Witchel of Scharff, Witchel & Co., Inc., 212-983-1060, for BioSpecifics/
 (BSTC)


CO: BioSpecifics Technologies Corp. ST: New York IN: MTC SU:

WB-OS -- NY046 -- 9365 08/04/93 12:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 4, 1993
Words:243
Previous Article:BONNIWELL NAMED TO APPLIANCE RECYCLING CENTERS OF AMERICA, INC. BOARD OF DIRECTORS
Next Article:ABBOTT LABORATORIES: INCREASING MINORITIES IN ENGINEERING FOCUS OF MEETING OF FORTUNE 250 CORPORATIONS AND HISTORICALLY BLACK COLLEGES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters